ViaDerma, Inc. (OTC: VDRM) is a specialty pharmaceutical company bringing new products to market. Vitastem is an award-winning topical antibiotic & first aid.
$VDRM Update: We received very positive feedback and have successfully completed the stability requirements for the Vitastem Ultra bacitracin formula. The company is on track to begin shipping @vitastem overseas in March.
The Global Wound Care Market Size & Trends - @vitastem is the best topical antibiotic for treating a variety of minor to severe wounds
https://t.co/6niDxQ2Kjn
#woundcare#diabeticwounds#burns
Update: $VDRM filings have been submitted to #OTCMarkets. Further updates on stability testing requirements completion and moving forward with international sales distribution for @vitastem are coming soon.
Update on Stability Testing: We're on track to finalize all (finally!) within the next few weeks. Due to a small staining issue with the formulas at the testing facility, they've been working hard to correct this immediately. - Dr. Otiko
Vitastem Ultra: A New & Innovative Topical Antibiotic That Can Help 2 Million US Diabetic Foot Ulcer Suffers Heal 10x Better https://t.co/84ptUyY07o
Battling Superbugs with Vitastem Ultra: A Beacon of Hope in the Fight Against HAIs That Cost US Healthcare About $45 Billion Annually https://t.co/34JXbet8II
Vitastem Ultra: This Game-Changer Antibiotic Is Expanding Sales Distribution into India, Egypt, The Middle East & Caribbean in 2024 https://t.co/3xKLYVu6Zl
Vitastem Ultra: A Game-Changer in Wound Care and Infection Prevention to Expand Sales Growth into India, The Middle East & Caribbean
https://t.co/f037JjeDA2
Vitastem Ultra: This Innovative Wound Treatment Can Help Quickly Reduce HAIs That Cost US Healthcare Upwards of $45 Billion Annually
https://t.co/XxDWRIUSVN
ViaDerma Moving Forward with Vitastem Ultra International Sales Expansion into India, The Caribbean & Middle East in Q1 2024
https://t.co/EeJrSJ8oG0